Everolimus and intensive behavioral therapy in an adolescent with tuberous sclerosis complex and severe behavior()()()

BACKGROUND: Self-injury and aggression have been reported in individuals with TSC (tuberous sclerosis complex), yet few data exist about treatment. Everolimus, an mTOR inhibitor, has been FDA-approved for subependymal giant cell astrocytomas (SEGAs) and renal angiomyolipomas in TSC. However, clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Gipson, Tanjala T., Jennett, Heather, Wachtel, Lee, Gregory, Mary, Poretti, Andrea, Johnston, Michael V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150649/
https://www.ncbi.nlm.nih.gov/pubmed/25667844
http://dx.doi.org/10.1016/j.ebcr.2013.06.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150649/
https://www.ncbi.nlm.nih.gov/pubmed/25667844
http://dx.doi.org/10.1016/j.ebcr.2013.06.004

Ejemplares similares